Boston Scientific enrolls the first patient in its MultiSENSE clinical trial which is designed to evaluate multiple physiologic sensors in the company's COGNIS cardiac resynchronization therapy defibrillators (CRT-Ds).
Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure. The first patient was enrolled by Paul Coffeen, MD, Austin Heart, Austin, Texas, where Jeffrey Whitehill, MD, Medical Chair, Electrophysiology Department, is the site's Principal Investigator.When combined with the Boston's Latitude Patient Management System, CRT-D sensors would be able to monitor a patient outside of a clinical setting and permit the Latitude system to deliver early notification to the physician when the patient's heart failure worsens. 'Heart failure is a complex disease and physicians use a number of diagnostics to assess a patient's condition and disease progression,' said John Boehmer, MD, Medical Director, Heart Failure Program and Professor of Medicine, Penn State Hershey Medical Center and Principal Investigator of the MultiSENSE trial. 'A multi-sensor design in an implantable device, with the predictive power of multiple data points, would enable physicians to take clinical action sooner to avoid hospitalization due to heart failure.' 'The MultiSENSE trial marks a significant step toward addressing the unmet needs of heart failure patients,' said Kenneth Stein, MD, Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group. 'Boston Scientific's unique multi-sensor approach is designed to allow our CRT-Ds to assess the same symptoms and data a doctor evaluates when seeing a heart failure patient in the office.' |
